STOCK TITAN

Akili, Inc. - $AKLI STOCK NEWS

Welcome to our dedicated page for Akili news (Ticker: $AKLI), a resource for investors and traders seeking the latest updates and insights on Akili stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akili's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akili's position in the market.

News
Rhea-AI Summary
Akili, Inc. announces leadership transition and shift to non-prescription business model
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
management
-
Rhea-AI Summary
Akili's EndeavorOTC, a video game treatment for adults with ADHD, is now available on Google Play for Android devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16%
Tags
none
-
Rhea-AI Summary
Akili, Inc. plans to transition to a non-prescription business model, aiming to increase consumer access and generate revenues that will support gross margins between 60 and 70 percent by late 2025. The company's focus on a consumer-led subscription model will reduce reliance on payers and intermediaries, allowing for more control over growth and a lasting, sustainable business. The non-prescription model has shown success with EndeavorOTC, which exceeded expectations in consumer demand, engagement, and retention in its first three months on the market. Akili plans to pursue regulatory approval for over-the-counter labeling of its treatment products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
Rhea-AI Summary
The Founders Roundtable event in downtown Chicago offers an opportunity for founders to connect and gain insights during uncertain economic times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.9%
Tags
Akili, Inc.

Nasdaq:AKLI

AKLI Rankings

AKLI Stock Data

31.56M
26.11M
23.26%
54.19%
0.16%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BOSTON